Park Avenue Securities’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.02M | Buy |
8,094
+1,011
| +14% | +$127K | 0.01% | 777 |
|
|
2025
Q1 | $783K | Buy |
7,083
+3
| +0% | +$332 | 0.01% | 694 |
|
|
2024
Q4 | $966K | Buy |
7,080
+1,336
| +23% | +$182K | 0.01% | 773 |
|
|
2024
Q3 | $662K | Sell |
5,744
-4,189
| -42% | -$483K | 0.01% | 862 |
|
|
2024
Q2 | $1.37M | Buy |
9,933
+363
| +4% | +$50K | 0.02% | 537 |
|
|
2024
Q1 | $1.32M | Buy |
9,570
+101
| +1% | +$13.9K | 0.02% | 540 |
|
|
2023
Q4 | $1.25M | Buy |
9,469
+528
| +6% | +$69.6K | 0.02% | 526 |
|
|
2023
Q3 | $1.01M | Buy |
+8,941
| New | +$1.01M | 0.02% | 557 |
|
|
2023
Q1 | – | Sell |
-8,553
| Closed | -$1.02M | – | 1006 |
|
|
2022
Q4 | $1.02M | Buy |
8,553
+31
| +0.4% | +$3.7K | 0.02% | 510 |
|
|
2022
Q3 | $905K | Sell |
8,522
-696
| -8% | -$73.9K | 0.02% | 488 |
|
|
2022
Q2 | $899K | Buy |
9,218
+1,300
| +16% | +$127K | 0.02% | 511 |
|
|
2022
Q1 | $742K | Buy |
7,918
+4,064
| +105% | +$381K | 0.01% | 588 |
|
|
2021
Q4 | $328K | Sell |
3,854
-1,923
| -33% | -$164K | 0.01% | 884 |
|
|
2021
Q3 | $554K | Buy |
5,777
+563
| +11% | +$54K | 0.01% | 598 |
|
|
2021
Q2 | $507K | Buy |
5,214
+1,136
| +28% | +$110K | 0.01% | 625 |
|
|
2021
Q1 | $397K | Buy |
4,078
+685
| +20% | +$66.7K | 0.01% | 666 |
|
|
2020
Q4 | $325K | Buy |
3,393
+317
| +10% | +$30.4K | 0.01% | 655 |
|
|
2020
Q3 | $296K | Buy |
3,076
+1,165
| +61% | +$112K | 0.01% | 576 |
|
|
2020
Q2 | $233K | Buy |
+1,911
| New | +$233K | 0.01% | 590 |
|